Last updated: February 17, 2026
What Is the Current Market Size and Growth Trend for Leukotriene Receptor Antagonists?
The global market for leukotriene receptor antagonists (LTRAs) was valued at approximately USD 1.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030. The primary drivers include increased prevalence of asthma and allergic rhinitis, expanded therapeutic indications, and pipeline drug developments.
What Are the Leading Drugs in the Class?
Montelukast remains the dominant drug within this class, holding over 85% of the market share in 2022. Zafirlukast follows with a smaller fraction, primarily used in specific geographic regions. Generic versions of montelukast entered the market in the late 2010s, intensifying price competition and expanding access.
How Are Patent Expirations Shaping Market Competition?
Key Patent Expirations
| Drug |
Patent Expiration |
Patent Type |
Year |
Impact |
| Montelukast |
2028 |
Composition of Matter |
2028 |
Entry of generics expected, heightening price competition |
| Zafirlukast |
2025 |
Method of Use |
2025 |
Generics can enter, reducing premiums |
The patent for montelukast’s composition of matter was granted in 1995 and is set to expire in 2028. Several method-of-use patents extend until 2030 but are considered weaker in defending against generic competition.
Patent Challenges and Litigation
In 2019, the FDA approved multiple generic versions of montelukast. Pfizer, the original manufacturer, filed patent disputes and legal challenges to delay market entry but faced mounting pressures. Patent courts in the US and EU have validated generic rights based on patent invalidity arguments and patent-life cycle strategies.
How Is the Patent Landscape Evolving?
Patent Filings and Patent Term Extensions
Major pharmaceutical companies have filed additional patents for novel formulations, combination therapies, and new dosages to extend exclusivity. For instance, patent applications for orally disintegrating tablet formulations or fixed-dose combinations are active through 2030.
Strategic Patent Extensions
Patent term extensions (PTEs) are used to compensate for regulatory delays. Brands like montelukast have sought PTEs to maintain market exclusivity into the next decade indirectly. These strategies often rely on secondary patents for formulations or manufacturing methods.
Geographic Patents
Patent protections vary globally. The US Patent and Trademark Office (USPTO) grants key patents until 2028, but patent rights in emerging markets such as India and China are less robust, leading to earlier generic entry.
What Are the Drivers and Barriers Affecting Future Market Growth?
Drivers:
- Rising asthma and allergic rhinitis prevalence: WHO reports 262 million cases of asthma worldwide (2020 data).
- Expanded indications: ongoing research evaluates LTRAs' role in atopic dermatitis and other inflammatory conditions.
- Increased use in pediatric and elderly populations.
Barriers:
- Patent cliffs: impending expiration of primary patents.
- Generic competition: lowering drug prices and market share.
- Regulatory challenges: safety concerns or approval delays for new indications.
Which Competitors Are Innovating or Expanding in This Class?
Key industry players include Pfizer, AstraZeneca, and GlaxoSmithKline. Pfizer's montelukast remains the most prescribed, but competitors are focusing on reformulations and combination regimens, such as montelukast with corticosteroids or antihistamines, seeking to extend market relevance.
Pipeline candidates are researching agents with improved bioavailability, fewer side effects, or alternative mechanisms, although few innovative drugs are expected to enter the market before 2030.
What Is the Outlook for Future Patent Filings and Market Entry?
Predictions indicate increased patent filings related to formulations, delivery mechanisms, and new uses through 2025. The expiration of core patents beginning in 2028 will likely lead to significant generic penetration, possibly reducing prices by up to 50% or more.
Emerging markets could see accelerated generic entry due to weaker patent enforcement, impacting global pricing and access.
Key Takeaways
- The leukotriene receptor antagonist market is valued at USD 1.5 billion (2022) with a CAGR of 4.2%.
- Montelukast dominates market share; patent expiration in 2028 will open opportunities for generics.
- Patent strategies include formulation patents, secondary patents, and patent term extensions.
- Patent expiries and genericization are primary growth constraints in the coming decade.
- Innovation focuses on formulations and combination therapies; new drug approvals are limited for this class.
FAQs
1. When will the patent for montelukast expire?
In the US, the primary patent for montelukast's composition of matter expires in 2028.
2. What is the potential impact of patent expirations on the market?
Patent expirations are expected to lead to increased generic competition, significantly lowering prices and reducing market dominance of branded drugs.
3. Are there any pipeline drugs expected to challenge existing LTRAs?
Current pipeline drugs focus primarily on reformulations or combination therapies rather than entirely novel mechanism agents. Few new entrants are expected before 2030.
4. How does patent protection differ internationally?
Patent protections are strongest in the US and Europe, with expiration dates similar to 2028-2030. Emerging markets often have weaker enforcement, enabling earlier generic entry.
5. What factors influence the growth of this drug class in the future?
Prevalence of target diseases, regulatory approval for new indications, patent strategies, and competition from generics primarily influence future growth.
References
- MarketWatch, "Leukotriene Receptor Antagonists Market Size," 2022.
- WHO, "Global Status Report on Asthma," 2020.
- U.S. Patent and Trademark Office, Patent Data Reports, 2022.
- FDA, "Drug Approvals and Patent Litigation Overview," 2019.
- IMS Health, "Pharmaceutical Market Trends," 2022.
